MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance
IRVINE, CA – October 15, 2026 ( GlobeNewswire ) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced preliminary unaudited revenue from continuing operations for the third quarter ended September 30, 2026, and suspends its full-year 2026 revenue guidance of $110–115 million.